Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study
Sri Gururangan(Boston Children's Hospital), L. Kun(St. Jude Children's Research Hospital), Sridhar Vajapeyam, Roger J. Packer(George Washington University), Amar Gajjar(St. Jude Children's Research Hospital), Henry S. Friedman(Duke Medical Center), Arzu Onar‐Thomas(St. Jude Children's Research Hospital), Richard J. Gilbertson(University of Cambridge), Sarah Goldman(Children's National), Tina Young Poussaint(Seattle Children's Hospital), James M. Boyett(Northwestern University), Jason Fangusaro(Lurie Children's Hospital)
Cited by 60
Related Papers
<i>TERT</i> promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal
|Proceedings of the National Academy of Sciences|2013|1.4k
Challenges to curing primary brain tumours
|Nature Reviews Clinical Oncology|2019|965
Early Experience Alters Brain Function and Structure
|PEDIATRICS|2004|884
Novel mutations target distinct subgroups of medulloblastoma
|Nature|2012|853
Integrated Molecular Genetic Profiling of Pediatric High-Grade Gliomas Reveals Key Differences With the Adult Disease
|Journal of Clinical Oncology|2010|657